Big Data in Aging and Age - Related Diseases

Big Data in Aging and Age - Related Diseases

Commercializing Aging Research Series Industry Overview BIG DATA IN AGING AND AGE - RELATED DISEASES Analysis of the Anti-Aging Market 1 aginganalytics.com bg-rf.org.uk biotech.ai BIG DATA IN AGING TABLE OF CONTENTS AND AGE - RELATED DISEASES TABLE OF CONTENTS..........................................................................................................................................3 INTRODUCTION.....................................................................................................................................................4 INDUSTRY OVERVIEW..........................................................................................................................................7 INDUSTRY TRENDS............................................................................................................................................10 CHALLENGES IN COMMERCIALIZING LONGEVITY RESEARCH...................................................................12 EARLY TRIALS AND FAILURES..........................................................................................................................14 Telomerase - Geron............................................................................................................................................14 Resveratrol - Elixir & Sirtris Pharmaceuticals..................................................................................................14 Contributing Parties: TRENDS IN BIG PHARMA...................................................................................................................................15 OPPORTUNITY AND MARKET SIZE..................................................................................................................16 COMPANY PROFILES.........................................................................................................................................18 Biogerontology Research Foundation (BGRF) Calico Life Sciences, LLC ..................................................................................................................................19 Key Personnel......................................................................................................................................................19 Aging Analytics Agency Background..........................................................................................................................................................19 Strategy................................................................................................................................................................20 AnalYsis................................................................................................................................................................20 Human LongevitY, Inc. (HLI)..............................................................................................................................22 Key Personnel......................................................................................................................................................22 Assisted by Background..........................................................................................................................................................22 Strategy................................................................................................................................................................22 VITAL analytical tool AnalYsis................................................................................................................................................................24 Insilico Medicine (ISM).......................................................................................................................................26 Key Personnel......................................................................................................................................................26 Background..........................................................................................................................................................26 Strategy................................................................................................................................................................27 AnalYsis................................................................................................................................................................27 Canada Cancer and Aging Research Laboratories, Inc (CCARL)..................................................................30 Key Personnel......................................................................................................................................................30 Background..........................................................................................................................................................30 Strategy................................................................................................................................................................30 AnalYsis.................................................................................................................................................................31 Vision Genomics, LLC (VG)................................................................................................................................32 Key Personnel......................................................................................................................................................32 Background..........................................................................................................................................................32 Strategy................................................................................................................................................................32 AnalYsis................................................................................................................................................................33 Atlas Regeneration, Inc......................................................................................................................................34 Key Personnel......................................................................................................................................................34 Background..........................................................................................................................................................34 Strategy................................................................................................................................................................35 AnalYsis................................................................................................................................................................35 CONCLUSION......................................................................................................................................................38 REFERENCES.......................................................................................................................................................42 Designed by Future Technologies Media Group 2 Executive Summary Analysis of the Anti-Aging Market 3 COMMERCIALIZING AGING RESEARCH SERIES COMMERCIALIZING AGING RESEARCH SERIES INTRODUCTIONINTRODUCTION As both the proportion of older people and the length in 2003 it was announced that the human genome As both the proportion of older people betes Federation (IDF) study estimated of life increase throughout andthe the world, length ofhow life increasewill aging throughout that had387 million been people sequenced, have diabetes there in was much optimism that the world, how will aging affect health 2014 and this disease caused at least affect health care and economiccare and costs? economic Age-related costs? Age-related USDwe 612 hadbillion entered dollars in healtha new expendi age -of human health where diseases such as cancer, heart disease, ture in 2014 – 11% of total spending on diseases such as cancer, heartstroke anddisease, diabetes stroke already and comprise a adults.conditions The IDF estimates like cancer that the and num -aging would be easily substantial economic and public health ber of people with diabetes will rise to diabetes already compriseburden. a substantial In 2012 World economic Health Organiza - 592 cured.million. The presumption was that it would be a simple tion reported 14.1 mln of new cases. The and public health burden. Agrowth recent rate analysis for cancer of cases global per year Whilematter some progress of decoding has been the made genes in in the genome sequence FIGURE 1: Relative life extension potential of biomedical interventions has decreased due to enhancements combating age-related illnesses, much cancer trends by the Economistin the technologies, Intelligence treatment Unit (EIU) became moreto needs determine to be done. the When causative in 2003 it genes or mutations that cheaper. Thus, the cost of full cancer was announced that the human genome estimated that the cost of thetreatment 13 million including new therapies cancer totaled had underliebeen sequenced, specific there pathological was much phenotypes suchas canceras or aging. With the causative function. Another speculative area is replacement and regeneration pharmacology hold sequencing individual human genomes along with $100 bln.

View Full Text

Details

  • File Type
    pdf
  • Upload Time
    -
  • Content Languages
    English
  • Upload User
    Anonymous/Not logged-in
  • File Pages
    23 Page
  • File Size
    -

Download

Channel Download Status
Express Download Enable

Copyright

We respect the copyrights and intellectual property rights of all users. All uploaded documents are either original works of the uploader or authorized works of the rightful owners.

  • Not to be reproduced or distributed without explicit permission.
  • Not used for commercial purposes outside of approved use cases.
  • Not used to infringe on the rights of the original creators.
  • If you believe any content infringes your copyright, please contact us immediately.

Support

For help with questions, suggestions, or problems, please contact us